Amgen, Inc. vs United States Copper Index Fund — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while United States Copper Index Fund trades at $40.55. The key difference: Amgen, Inc. pays a 2.43% dividend while United States Copper Index Fund pays none. Which is the better fit depends on your goals.
| AMGN | CPER | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $417.20 | $40.85 |
52-Week Low | $271.18 | $27.57 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →